Monopar Therapeutics
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
MNPR$73.75+3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following exhibits are filed as part of this Quarterly Report on Form 10-Q.
| Exhibit | Document | Incorporated by Reference From: |
| 4.1 | Form of Pre-Funded Warrant | Form 8-K filed on September 24, 2025 |
| 10.1 | Underwriting Agreement, dated September 23, 2025, by and among Monopar Therapeutics Inc., Morgan Stanley & Co. LLC, Leerink Partners LLC, and Barclays Capital Inc. | Form 8-K filed on September 24, 2025 |
| 10.2 | Share Purchase Agreement, dated September 24, 2025, by and between Monopar Therapeutics Inc. and Tactic Pharma, LLC. | Form 8-K filed on September 24, 2025 |
| 31.1 | Certification of Chandler D. Robinson, Chief Executive Officer | Filed herewith |
| 31.2 | Certification of Quan Vu, Chief Financial Officer | Filed herewith |
| 32.1 | Certification of Chandler D. Robinson, Chief Executive Officer and Quan Vu, Chief Financial Officer | Filed herewith |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase | |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.